Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion

Despite the important role of apolipoprotein E (apoE) secretion from astrocytes in brain lipid metabolism and the strong association of apoE4, one of the human apoE isoforms, with sporadic and late onset forms of Alzheimer’s disease (AD) little is known about the regulation of astrocytic apoE. Utilizing annotated chemical libraries and a phenotypic screening strategy that measured apoE secretion from a human astrocytoma cell line, inhibition of pan class I histone deacetylases (HDACs) was identified as a mechanism to increase apoE secretion. Knocking down select HDAC family members alone or in combination revealed that inhibition of the class I HDAC family was responsible for enhancing apoE secretion. Knocking down LXRα and LXRβ genes revealed that the increase in astrocytic apoE in response to HDAC inhibition occurred via an LXR-independent pathway. Collectively, these data suggest that pan class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion.

[1]  W. Möbius,et al.  Defective cholesterol clearance limits remyelination in the aged central nervous system , 2018, Science.

[2]  A. Fagan,et al.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.

[3]  Bradley T. Hyman,et al.  Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes , 2016, Proceedings of the National Academy of Sciences.

[4]  D. Michaelson APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[5]  D. Michaelson,et al.  Reversal of apoE4-Driven Brain Pathology and Behavioral Deficits by Bexarotene , 2014, The Journal of Neuroscience.

[6]  Peter Tontonoz,et al.  Liver X receptors in lipid metabolism: opportunities for drug discovery , 2014, Nature Reviews Drug Discovery.

[7]  R. Ryan,et al.  Impact of apolipoprotein E on Alzheimer's disease. , 2013, Current Alzheimer research.

[8]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[9]  N. Mitro,et al.  Linking epigenetics to lipid metabolism: Focus on histone deacetylases , 2012, Molecular membrane biology.

[10]  S. D’Mello,et al.  Histone Deacetylase-1 (HDAC1) Is a Molecular Switch between Neuronal Survival and Death* ♦ , 2012, The Journal of Biological Chemistry.

[11]  G. Landreth,et al.  Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease , 2012, The Journal of Neuroscience.

[12]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[13]  S. Haggarty,et al.  An epigenetic blockade of cognitive functions in the neurodegenerating brain , 2012, Nature.

[14]  M. Wood,et al.  HDAC3 and the molecular brake pad hypothesis , 2011, Neurobiology of Learning and Memory.

[15]  D. Holtzman,et al.  Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ Phagocytosis , 2011, Journal of Neuroscience.

[16]  K. Bales,et al.  Reduced levels of human apoE4 protein in an animal model of cognitive impairment , 2011, Neurobiology of Aging.

[17]  Marcelo A. Wood,et al.  HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation , 2010, The Journal of Neuroscience.

[18]  J. Herz,et al.  ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling , 2010, Proceedings of the National Academy of Sciences.

[19]  Yan Leng,et al.  Multiple roles of HDAC inhibition in neurodegenerative conditions , 2009, Trends in Neurosciences.

[20]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[21]  E. Olson,et al.  Histone Deacetylases 1 and 2 Form a Developmental Switch That Controls Excitatory Synapse Maturation and Function , 2009, The Journal of Neuroscience.

[22]  M. Wood,et al.  Modulation of long-term memory for object recognition via HDAC inhibition , 2009, Proceedings of the National Academy of Sciences.

[23]  S. Haggarty,et al.  HDAC2 negatively regulates memory formation and synaptic plasticity , 2009, Nature.

[24]  M. Pangalos,et al.  Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels , 2008, The Journal of Neuroscience.

[25]  A. Kozikowski,et al.  Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. , 2008, Journal of medicinal chemistry.

[26]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[27]  M. Staufenbiel,et al.  Expression profiling in APP23 mouse brain: inhibition of Aβ amyloidosis and inflammation in response to LXR agonist treatment , 2007, Molecular Neurodegeneration.

[28]  N. Mitro,et al.  Insights in the regulation of cholesterol 7α‐hydroxylase gene reveal a target for modulating bile acid synthesis , 2007, Hepatology.

[29]  T. Comery,et al.  The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease , 2007, Molecular and Cellular Neuroscience.

[30]  K. Weisgraber,et al.  Apolipoprotein E structure: insights into function. , 2006, Trends in biochemical sciences.

[31]  K. Weisgraber,et al.  Effect of Domain Interaction on Apolipoprotein E Levels in Mouse Brain , 2005, The Journal of Neuroscience.

[32]  Xianlin Han,et al.  ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE* , 2004, Journal of Biological Chemistry.

[33]  L. Bernier,et al.  Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain* , 2004, Journal of Biological Chemistry.

[34]  S. Paul,et al.  A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes , 2004, Journal of neurochemistry.

[35]  C. Allis,et al.  Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. , 2003, Molecular cancer therapeutics.

[36]  Suzhen Li,et al.  Induction of Human Liver X Receptor α Gene Expression Via an Autoregulatory Loop Mechanism , 2002 .

[37]  J. Sweatt,et al.  Increased Histone Acetyltransferase and Lysine Acetyltransferase Activity and Biphasic Activation of the ERK/RSK Cascade in Insular Cortex During Novel Taste Learning , 2001, The Journal of Neuroscience.

[38]  Johnm . Taylor,et al.  Two Distal Downstream Enhancers Direct Expression of the Human Apolipoprotein E Gene to Astrocytes in the Brain , 2001, The Journal of Neuroscience.

[39]  D. Mangelsdorf,et al.  LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Johnm . Taylor,et al.  Duplicated Downstream Enhancers Control Expression of the Human Apolipoprotein E Gene in Macrophages and Adipose Tissue* , 2000, Journal of Biological Chemistry.

[41]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[42]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[43]  A Rostagno,et al.  Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. , 2000, The Biochemical journal.

[44]  T. Suzuki,et al.  Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. , 1999, Journal of medicinal chemistry.

[45]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[47]  R. Mahley,et al.  Human apolipoprotein E: the Alzheimer's disease connection , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  J. Haines,et al.  Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease , 1995, Neurology.

[49]  G. Getz,et al.  Purification of Apolipoprotein E Attenuates Isoform-specific Binding to -Amyloid (*) , 1995, The Journal of Biological Chemistry.

[50]  J. Stowell,et al.  The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. , 1995, Journal of medicinal chemistry.

[51]  G. Getz,et al.  Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.

[52]  A. Hagenbeek,et al.  Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia. , 1993, Cancer research.

[53]  O. Myklebost,et al.  A physical map of the apolipoprotein gene cluster on human chromosome 19 , 1988, Human Genetics.

[54]  C. Wahlestedt,et al.  Histone deacetylases (HDACs) and brain function , 2015, Neuroepigenetics.

[55]  V. Narayanaswami,et al.  Apolipoprotein E: from lipid transport to neurobiology. , 2011, Progress in lipid research.

[56]  Gui-rong Zhang,et al.  Development and Stem Cells Research Article , 2022 .